Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 151 results:
Συντάκτης Τίτλος [ Τύπος] Έτος Φίλτρα: Συντάκτης is Mikhailidis, Dimitri P [Clear All Filters]
Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus..
Nat Clin Pract Endocrinol Metab. 5(1), 16-7.
(2009). Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property"..
Dig Liver Dis. 45(1), 82-3.
(2013). Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population..
Curr Med Res Opin. 26(3), 713-9.
(2010). A comparison of the aldosterone-blocking agents eplerenone and spironolactone..
Clin Cardiol. 32(4), 230.
(2009). Concurrent blood pressure, glycemic and lipid control for the prevention of vascular complications of type II diabetes mellitus: a long overdue objective?.
Curr Vasc Pharmacol. 8(1), 1-4.
(2010). Contrast-Induced Nephropathy: An "All or None" Phenomenon?.
Angiology. 66(6), 508-13.
(2015). CORONA, statins, and heart failure: who lost the crown?.
Angiology. 59(1), 5-8.
(2008). Current treatment for nonalcoholic fatty liver disease..
Expert Opin Pharmacother. 12(13), 2141-2; author reply 2142.
(2011). The DEFINE study: a bright future for CETP inhibitors?.
Expert Opin Investig Drugs. 20(3), 311-4.
(2011). Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?.
Expert Opin Pharmacother. 8(14), 2267-77.
(2007). Do we need to consider inflammatory markers when we treat atherosclerotic disease?.
Atherosclerosis. 200(1), 1-12.
(2008). Dyslipidaemia, hypercoagulability and the metabolic syndrome..
Curr Vasc Pharmacol. 4(3), 175-83.
(2006). Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics..
Nat Rev Cardiol. 11(2), 72-4.
(2014). Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment..
Open Cardiovasc Med J. 5, 24-34.
(2011). Dyslipidemia as a risk factor for ischemic stroke..
Curr Top Med Chem. 9(14), 1291-7.
(2009). Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases..
Open Cardiovasc Med J. 5, 85-9.
(2011). Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent?.
Curr Vasc Pharmacol. 10(3), 374-7.
(2012). The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis..
Curr Vasc Pharmacol. 8(6), 792-803.
(2010). Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study..
Curr Med Res Opin. 22(5), 873-83.
(2006). Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report..
Curr Vasc Pharmacol. 12(3), 505-11.
(2014). Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with CHD and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study..
Nephrol Dial Transplant. 22(1), 118-27.
(2007). The effect of statins on semen parameters in patients with hypercholesterolemia: A systematic review..
Andrology. 9(5), 1504-1511.
(2021). Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review..
Curr Med Res Opin. 29(10), 1263-74.
(2013). Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus..
Expert Opin Ther Targets. 15(4), 401-20.
(2011).
(2008).